Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Allergan And Valeant Expand In Dermatology

by Lisa M. Jarvis
July 25, 2011 | A version of this story appeared in Volume 89, Issue 30

Three dermatology businesses have changed hands in recent weeks. Allergan is paying $75 million up front and up to $200 million in milestones for privately held Vicept Therapeutics. Vicept, a Malvern, Penn.-based dermatology firm, was started in 2009 to commercialize V-101, a topical cream for the treatment of the redness associated with rosacea. It has since completed two Phase II studies. Separately, Valeant Pharmaceuticals has snapped up Johnson & Johnson’s Ortho Dermatologics division for $345 million. The deal came just days after Valeant agreed to fork over $425 million for Sanofi’s dermatology unit, Dermik, along with the global rights to the wrinkle filler Sculptra Aesthetic.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.